> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Workshop on Erythropoietic Protoporphyria Treatments
- URL: https://www.fdaweb.com/workshop-on-erythropoietic-protoporphyria-treatments/
- Published: 2016-07-01T12:00:00.000Z
- Updated: 2026-09-14T21:12:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136109

*Federal Register* Notice: FDA is sponsoring a public workshop 10/24 and seeking public comment on Erythropoietic Protoporphyria (EPP). The workshop is intended to discuss how best to facilitate and expedite the development of safe and effective drug therapies to treat signs and symptoms related to EPP. FDA will provide information for, and gain perspective from, patients and patient advocacy organizations, health care providers, academic experts, and industry on disease symptoms and its impact on daily life, experience with current treatment regimens for EPP, and various aspects of clinical development of products intended to treat EPP. The workshop will be held from 10 a.m. to 4 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. Contact **Meghana Chalasani** (240) 402-6525, Meghana.Chalasani@fda.hhs.gov. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-07-01/pdf/2016-15662.pdf?ref=fdaweb.com)